7.3 Adrenal & Pituitary Disorders: Adrenal Insufficiency, Cushing's, Hyperaldosteronism & Hypopituitarism

Adrenal & Pituitary Disorders: Adrenal Insufficiency, Cushing's, Hyperaldosteronism & Hypopituitarism

The adrenal glands and the hypothalamic-pituitary neuroendocrine axis orchestrate systemic homeostasis, hemodynamic vascular tone, extracellular fluid volume, glucose counter-regulation, and cellular stress adaptation. Disruption of these neuroendocrine circuits generates complex clinical syndromes with significant morbidity and mortality if unrecognized in primary care.

For the AGPCNP, board certification demands precision in adrenal steroidogenic pathways, diagnostic hormone stimulation and suppression protocols, glucocorticoid replacement and "sick-day" rules, mineralocorticoid excess screening, and osmoregulatory fluid-electrolyte management.

---

1. Adrenal Anatomy & Steroidogenesis Pathways

The adrenal gland is functionally divided into the outer Cortex (derived from mesoderm, comprising 90% of glandular volume) and the inner Medulla (derived from neural crest ectoderm):

+---------------------------------------------------------------------------------------------------+
|                         ADRENAL CORTEX & MEDULLA FUNCTIONAL ZONES                                 |
|                                                                                                   |
|   ZONE (OUTER TO INNER)        PRIMARY HORMONE CLASS     REGULATORY DRIVER     KEY ENZYME/PRODUCT |
|   ---------------------------------------------------------------------------------------------   |
|   1. ZONA GLOMERULOSA (15%)    Mineralocorticoids        RAAS / Angiotensin II Aldosterone        |
|                                (Salt Regulation)         & Serum Potassium     Synthase           |
|   2. ZONA FASCICULATA (75%)    Glucocorticoids           Pituitary ACTH        11-Beta-Hydroxylase|
|                                (Sugar Regulation)                              -> Cortisol        |
|   3. ZONA RETICULARIS (10%)    Adrenal Androgens         Pituitary ACTH        DHEA, DHEA-S,      |
|                                (Sex Regulation)                                Androstenedione    |
|   ---------------------------------------------------------------------------------------------   |
|   4. ADRENAL MEDULLA           Catecholamines            Sympathetic Nervous   Chromaffin Cells   |
|                                (Stress / Fight-Flight)   System (ACh)          -> Epi / Norepi    |
+---------------------------------------------------------------------------------------------------+
|   MNEMONIC: "GFR" = Salt, Sugar, Sex (The deeper you go, the sweeter it gets!)                   |
+---------------------------------------------------------------------------------------------------+

---

2. Adrenal Insufficiency: Primary, Secondary, Tertiary & Acute Adrenal Crisis

+---------------------------------------------------------------------------------------------------+
|                         ADRENAL INSUFFICIENCY PATHOPHYSIOLOGICAL MATRIX                           |
|                                                                                                   |
|   CLINICAL PARAMETER        PRIMARY (ADDISON'S DISEASE)        SECONDARY / TERTIARY AI            |
|   ---------------------------------------------------------------------------------------------   |
|   Site of Pathology         Adrenal Cortex Destruction         Pituitary (ACTH) / Hypothalamus    |
|   Most Common Etiology      Autoimmune Adrenalitis (80%)       Abrupt Glucocorticoid Withdrawal   |
|                             (21-hydroxylase Abs), TB, Infarct  Pituitary Adenoma / Apoplexy       |
|   Cortisol Level            DECREASED ($\downarrow$)            DECREASED ($\downarrow$)           |
|   Plasma ACTH Level         **MARKETLY ELEVATED** ($\uparrow$) **LOW OR INAPPROPRIATELY NORMAL**  |
|   Aldosterone Level         **DECREASED** ($\downarrow$)        **NORMAL** (Preserved via RAAS)   |
|   Serum Potassium           **HYPERKALEMIA** ($\uparrow$)      **NORMAL**                         |
|   Serum Sodium              **HYPONATREMIA** ($\downarrow$)    **HYPONATREMIA** (Euvolemic/SIADH) |
|   Integumentary Signs       **DIFFUSE HYPERPIGMENTATION**      **NO HYPERPIGMENTATION** (Pale)    |
|                             (Buccal mucosa, palmar creases)                                       |
|   Required Replacement      Hydrocortisone + Fludrocortisone   Hydrocortisone ALONE               |
+---------------------------------------------------------------------------------------------------+

A. Primary Adrenal Insufficiency (Addison's Disease)

• Pathophysiology: Autoimmune destruction of all three adrenal cortical zones mediated by autoantibodies against the 21-hydroxylase enzyme. Loss of cortisol eliminates negative feedback on the anterior pituitary and hypothalamus, triggering massive secretion of pro-opiomelanocortin (POMC). POMC is cleaved into ACTH and Melanocyte-Stimulating Hormone ($\alpha$-MSH), which stimulates melanocortin-1 receptors on dermal melanocytes.
• Clinical Manifestations:
  • Hyperpigmentation: Pathognomonic bronze darkening of sun-exposed and unexposed skin, palmar creases, extensor surfaces (knuckles, elbows, knees), vermilion border of the lips, and buccal mucosa.
  • Hypoaldosteronism: Renal sodium and water wasting with potassium and hydrogen retention $\rightarrow$ severe orthostatic hypotension, hypovolemia, intense salt craving, hyperkalemia, hyponatremia, and non-anion gap metabolic acidosis.
  • Hypocortisolemia: Profound chronic fatigue, generalized weakness, anorexia, unintentional weight loss, gastrointestinal symptoms (nausea, vomiting, diffuse abdominal cramping), fasting hypoglycemia, and eosinophilia.

B. Secondary and Tertiary Adrenal Insufficiency

• Secondary AI: Impaired pituitary ACTH secretion (pituitary macroadenomas, Sheehan syndrome, craniopharyngiomas, lymphocytic hypophysitis from checkpoint inhibitors).
• Tertiary AI: Impaired hypothalamic CRH secretion, overwhelmingly caused by iatrogenic suppression following chronic exogenous corticosteroid therapy (e.g., prednisone $\ge 5\text{ mg/day}$ for $\ge 3\text{ weeks}$). Abrupt cessation leaves the atrophic hypothalamic-pituitary-adrenal (HPA) axis unable to respond to physiological stress.
• Key Clinical Distinctions: Patients with secondary/tertiary AI exhibit pallor (alabaster skin) rather than hyperpigmentation. Aldosterone secretion remains intact because the zona glomerulosa is regulated by the renin-angiotensin system, not ACTH; therefore, hyperkalemia does NOT occur.

C. Stepwise Diagnostic Protocol for Adrenal Insufficiency

+---------------------------------------------------------------------------------------------------+
|                         ADRENAL INSUFFICIENCY DIAGNOSTIC FLOWCHART                                |
|                                                                                                   |
|                     [SUSPECTED ADRENAL INSUFFICIENCY: FATIGUE, HYPOTENSION]                       |
|                                                |                                                  |
|                                                v                                                  |
|                              [8:00 AM SERUM CORTISOL + PLASMA ACTH]                               |
|                                                |                                                  |
|         +--------------------------------------+--------------------------------------+           |
|         |                                      |                                      |           |
|         v                                      v                                      v           |
|   [CORTISOL < 3 mcg/dL]              [CORTISOL 3 - 18 mcg/dL]               [CORTISOL > 18 mcg/dL]|
|   Diagnostic of Adrenal              INDETERMINATE ZONE                     ADRENAL INSUFFICIENCY |
|   Insufficiency                      (Proceed to Cosyntropin Test)          EXCLUDED              |
|         |                                      |                                                  |
|         +--------------------------------------+                                                  |
|                                                |                                                  |
|                                                v                                                  |
|                        [HIGH-DOSE COSYNTROPIN (ACTH) STIMULATION TEST]                            |
|                        - Administer 250 mcg Cosyntropin (Synthetic ACTH) IV/IM                    |
|                        - Measure Serum Cortisol at 0, 30, and 60 minutes                          |
|                                                |                                                  |
|                       +------------------------+------------------------+                         |
|                       |                                                 |                         |
|                       v                                                 v                         |
|          [PEAK CORTISOL < 18 mcg/dL]                       [PEAK CORTISOL >= 18 mcg/dL]           |
|          CONFIRMS ADRENAL INSUFFICIENCY                    NORMAL ADRENAL FUNCTION                |
|                       |                                                                           |
|         +-------------+-------------+                                                             |
|         |                           |                                                             |
|         v                           v                                                             |
|   [HIGH ACTH (>100 pg/mL)]    [LOW / NORMAL ACTH (<20 pg/mL)]                                     |
|   = PRIMARY ADRENAL           = SECONDARY / TERTIARY                                              |
|     INSUFFICIENCY               ADRENAL INSUFFICIENCY                                             |
|   - Check 21-Hydroxylase Abs  - Perform Pituitary MRI /                                           |
|   - Order Adrenal CT scan       Assess for steroid withdrawal                                     |
+---------------------------------------------------------------------------------------------------+

D. Chronic Maintenance & "Sick-Day" Patient Education

• Glucocorticoid Replacement: Hydrocortisone (15–25 mg/day PO) divided into two or three doses to mimic physiological circadian rhythm (e.g., 10–15 mg upon waking at 7:00 AM, 5 mg at 12:00 PM, and 2.5–5 mg at 5:00 PM; avoid evening doses to prevent insomnia). Alternatively, Prednisone (3–5 mg once daily in the morning).
• Mineralocorticoid Replacement (Primary AI Only): Fludrocortisone (0.05–0.2 mg PO daily in the morning). Titrate to normalize blood pressure, eliminate orthostasis, and achieve normal serum sodium/potassium and PRA levels. Encourage liberal dietary sodium intake.
• Sick-Day Rules (Mandatory Board Knowledge):
  • Mild Illness / Low Fever (<38°C): Double the baseline oral hydrocortisone dose until recovery (usually 2–3 days).
  • Severe Illness / High Fever (>38.5°C) / Antibiotic-Requiring Infections: Triple the baseline oral hydrocortisone dose.
  • Severe Gastroenteritis / Intractable Vomiting / Major Trauma / Surgery: Patients cannot absorb oral medications. Must immediately inject Hydrocortisone 100 mg IM (emergency home kit) and present to the nearest Emergency Department.
  • Medical Alert: All patients must wear a Medical Alert bracelet/necklace and carry an emergency prefilled hydrocortisone auto-injector.

E. Acute Adrenal Crisis (Addisonian Crisis)

• Clinical Presentation: Refractory hypovolemic shock unresponsive to IV fluid boluses and standard vasopressors, high fever, severe generalized abdominal pain with guarding (mimicking acute surgical abdomen), intractable vomiting, lethargy, stupor, and hypoglycemia.
• Immediate Resuscitation Protocol (Never Delay for Diagnostic Testing):
  1. IV Access & Fluids: Rapid infusion of 0.9% Normal Saline + 5% Dextrose (to correct hypovolemia, hyponatremia, and hypoglycemia; run $1\text{--}2\text{ L}$ over first 1–2 hours).
  2. IV Stress-Dose Steroids: Administer Hydrocortisone 100 mg IV STAT, followed by 50 to 100 mg IV every 6 hours (or 200 mg/24h continuous infusion). (At doses $\ge 100\text{ mg}$, hydrocortisone provides maximum cross-mineralocorticoid receptor activity; fludrocortisone is unnecessary during acute IV resuscitation).
  3. Diagnostic Pearl: If a cosyntropin stimulation test has not yet been performed and confirmation is urgently desired, administer Dexamethasone 4 mg IV STAT instead of hydrocortisone. Dexamethasone does not cross-react with the serum cortisol radioimmunoassay!

---

3. Cushing's Syndrome: Etiologies, Diagnostic Triad & Localization Algorithm

+---------------------------------------------------------------------------------------------------+
|                         CUSHING'S SYNDROME CLINICAL SPECTRUM                                      |
|                                                                                                   |
|   ETIOLOGY                    ACTH DEPENDENCY   SERUM ACTH    HIGH-DOSE DST    CRH STIMULATION    |
|   ---------------------------------------------------------------------------------------------   |
|   Exogenous Steroids          Independent       Suppressed    No effect        No effect          |
|   (Most Common Overall)       (Iatrogenic)                                                        |
|   Cushing's Disease           ACTH-Dependent    Elevated /    **>50% CORTISOL  **INCREASED ACTH   |
|   (Pituitary ACTH Adenoma)    (70% endogenous)  Normal        SUPPRESSION**    & CORTISOL**       |
|   Ectopic ACTH Secretion      ACTH-Dependent    **MARKETLY    NO SUPPRESSION   NO RESPONSE        |
|   (Small Cell Lung Cancer)    (15% endogenous)  ELEVATED**    (<50% drop)                         |
|   Adrenal Adenoma / Carcinoma ACTH-Independent  **SUPPRESSED  NO SUPPRESSION   NO RESPONSE        |
|   (Autonomous Adrenal Output) (15% endogenous)  (<5 pg/mL)**  (<50% drop)                         |
+---------------------------------------------------------------------------------------------------+

Clinical Phenotype of Hypercortisolemia:

• Fat Redistribution: Centripetal/truncal obesity, rounded "moon facies", dorsocervical fat pad ("buffalo hump"), and prominent supraclavicular fat pads.
• Protein Catabolism & Musculoskeletal: Marked proximal muscle weakness (inability to stand from a chair without using arms; selective type II muscle fiber atrophy), thin fragile skin with wide violaceous striae (>1 cm width on abdomen, flanks, breasts), easy spontaneous ecchymoses/bruising, severe osteopenia/osteoporosis with pathological vertebral compression fractures.
• Metabolic & Vascular: Secondary hypertension, impaired glucose tolerance / new-onset T2DM, hypercoagulability (high DVT/PE risk), poor wound healing, opportunistic fungal infections.
• Neuropsychiatric & Gonadal: Emotional lability, mania, depression, insomnia, cognitive dysfunction; hirsutism and oligomenorrhea/amenorrhea in females (due to adrenal androgens).

Multi-Tiered Diagnostic Protocol for Hypercortisolemia

+---------------------------------------------------------------------------------------------------+
|                         CUSHING'S SYNDROME STEPWISE DIAGNOSTIC WORKUP                             |
|                                                                                                   |
|   [STEP 1: RULE OUT EXOGENOUS GLUCOCORTICOID USE (ORAL, INHALED, TOPICAL, INJECTIONS)]            |
|                                                |                                                  |
|                                                v                                                  |
|   [STEP 2: CONFIRM HYPERCORTISOLEMIA (MUST HAVE >= 2 ABNORMAL FIRST-LINE SCREENING TESTS)]        |
|   - 1. 24-Hour Urinary Free Cortisol (UFC): Elevated > 3x upper limit of normal.                  |
|   - 2. Late-Night Salivary Cortisol (measured at 11:00 PM on 2 consecutive nights): Elevated.     |
|   - 3. 1-mg Overnight Dexamethasone Suppression Test (DST): Give 1 mg at 11:00 PM; measure       |
|        8:00 AM serum cortisol. Positive / Abnormal if Cortisol >= 1.8 mcg/dL (Fails to suppress). |
|                                                |                                                  |
|                                                v                                                  |
|   [STEP 3: MEASURE PLASMA ACTH LEVEL (DETERMINE ACTH-DEPENDENCY)]                                 |
|                                                |                                                  |
|                       +------------------------+------------------------+                         |
|                       |                                                 |                         |
|                       v                                                 v                         |
|         [ACTH SUPPRESSED (< 5 pg/mL)]                     [ACTH NORMAL OR ELEVATED (>= 15-20)]    |
|         = ACTH-INDEPENDENT CUSHING'S                      = ACTH-DEPENDENT CUSHING'S              |
|                       |                                                 |                         |
|                       v                                                 v                         |
|         [ORDER ADRENAL CT / MRI]                          [HIGH-DOSE (8-mg) DST OR CRH TEST]      |
|         - Adrenal Adenoma vs. Carcinoma                   - High Suppression (>50%) = Pituitary   |
|         - Treatment: Laparoscopic Adrenalectomy           - No Suppression = Ectopic Source       |
|                                                                         |                         |
|                                                           +-------------+-------------+           |
|                                                           |                           |           |
|                                                           v                           v           |
|                                                  [PITUITARY MRI]             [CHEST/ABDOMEN CT]   |
|                                                  = Cushing's Disease         = Ectopic ACTH (SCLC)|
|                                                  - Transsphenoidal Surgery   - Resection/Chemo    |
+---------------------------------------------------------------------------------------------------+

---

4. Primary Aldosteronism (Conn's Syndrome)

Primary aldosteronism is the single most common identifiable cause of secondary hypertension, accounting for 5–10% of all hypertensive adults and up to 20% of patients with resistant hypertension.

A. Pathophysiology & Etiologies

Autonomous excess aldosterone secretion from the zona glomerulosa acts on the mineralocorticoid receptors of the renal cortical collecting duct principal cells $\rightarrow$ upregulation of epithelial sodium channels (ENaC) and $\text{Na}^+/\text{K}^+\text{-ATPase}$ pumps $\rightarrow$ sodium retention, plasma volume expansion, potassium wasting, and urinary hydrogen ion secretion.

• Bilateral Idiopathic Adrenal Hyperplasia (IAH, 60–65%): Diffuse hyperplasia of both adrenal glands.
• Aldosterone-Producing Adenoma (APA / Conn's Disease, 30–35%): Unilateral benign solitary cortical neoplasm.

B. Clinical Clues Triggering Screening

• Resistant hypertension ($\ge 130/80\text{ mmHg}$ on 3 maximally tolerated antihypertensive agents including a diuretic, or controlled on $\ge 4$ medications).
• Severe hypertension ($\text{BP} \ge 150/100\text{ mmHg}$ on two separate measurements).
• Hypertension with spontaneous or diuretic-induced hypokalemia.
• Hypertension with incidental adrenal mass (adrenal incidentaloma).
• Hypertension with a family history of early-onset hypertension or stroke at age $<40\text{ years}$.

[!NOTE] The Normokalemia Clinical Pearl: More than 50% of patients with confirmed primary aldosteronism are normokalemic! Normal serum potassium must never be used to exclude primary aldosteronism in patients with resistant or severe hypertension.

C. Screening, Confirmation & Subtyping Protocol

+---------------------------------------------------------------------------------------------------+
|                         PRIMARY ALDOSTERONISM DIAGNOSTIC WORKUP                                   |
|                                                                                                   |
|   [STEP 1: SCREENING - MORNING PAIRED PAC AND PRA]                                                |
|   - Patient must be normokalemic (replete K+) and off MRAs (spironolactone/eplerenone) x 4-6 wks. |
|   - Measure morning ambulatory Plasma Aldosterone Concentration (PAC) & Plasma Renin Activity (PRA)|
|   - Positive Screening Result: ARR (PAC/PRA ratio) >= 20 to 30 WITH PAC >= 15 ng/dL               |
|                                     |                                                             |
|                                     v                                                             |
|   [STEP 2: CONFIRMATORY TESTING]                                                                  |
|   - Oral Sodium Loading Test OR IV Saline Infusion Test (2 L 0.9% NaCl over 4 hours).             |
|   - Post-infusion PAC > 10 ng/dL confirms autonomous aldosterone secretion (failure to suppress). |
|                                     |                                                             |
|                                     v                                                             |
|   [STEP 3: SUBTYPE DIFFERENTIATION (SURGICAL CANDIDATES)]                                         |
|   - Thin-Slice Adrenal CT Scan to exclude large adrenocortical carcinoma.                         |
|   - **ADRENAL VEIN SAMPLING (AVS, Gold Standard):** Catheterization of bilateral adrenal veins to  |
|     measure aldosterone/cortisol ratios; differentiates unilateral APA from bilateral IAH.       |
|                                     |                                                             |
|         +---------------------------+---------------------------+                             |
|         |                                                       |                             |
|         v                                                       v                             |
|   [UNILATERAL APA (LATERALIZATION)]                       [BILATERAL HYPERPLASIA (IAH)]       |
|   - Treatment: Laparoscopic Unilateral                    - Treatment: Medical Management     |
|     Adrenalectomy (Curative of HTN in 50-80%)               * Mineralocorticoid Receptor      |
|                                                               Antagonists (MRAs):             |
|                                                               SPIRONOLACTONE (25-100 mg/day)  |
|                                                               or EPLERENONE (50-100 mg/day)   |
+---------------------------------------------------------------------------------------------------+

---

5. Pheochromocytoma: The Paroxysmal Triad & Alpha-Blockade Rules

Pheochromocytomas are rare catecholamine-secreting neuroendocrine tumors arising from chromaffin cells of the adrenal medulla (extra-adrenal tumors are termed paragangliomas). Follows the "Rule of 10s": 10% bilateral, 10% extra-adrenal, 10% malignant, 10% familial/genetic (MEN 2A/2B, VHL, NF1).

A. The Classic Paroxysmal Triad ("The 3 Ps")

1. Pounding Cephalea (Severe Headache)
2. Profuse Perspiration (Diaphoresis)
3. Palpitations & Tachycardia Accompanied by paroxysmal or sustained severe, labile hypertension, pallor, tremor, and impending sense of doom.

B. Diagnostic Testing

• Initial Screening: Measure Plasma Free Metanephrines (highest sensitivity, 96–99%) or 24-hour Urinary Fractionated Metanephrines and Catecholamines.
• Localization: Abdominal/pelvic CT or MRI with IV contrast after biochemical confirmation; ${}^{123}\text{I-MIBG}$ scintigraphy or ${}^{68}\text{Ga-DOTATATE}$ PET for extra-adrenal/metastatic lesions.

[!CAUTION] The Absolute Alpha-Blockade Mandate: Never administer a beta-blocker as monotherapy to a patient with pheochromocytoma! Pre-operative medical stabilization requires Alpha-Adrenergic Blockade FIRST (e.g., non-selective irreversible $\alpha$-blocker Phenoxybenzamine 10 mg BID titrated for 10–14 days, or selective $\alpha_1$-blockers like doxazosin) to achieve blood pressure normalization and volume expansion. Only AFTER adequate alpha-blockade is established should a beta-blocker (propranolol/metoprolol) be added to control reflex tachycardia. Giving a beta-blocker first eliminates $\beta_2$-mediated vasodilation, leaving $\alpha_1$-vasoconstriction unopposed, precipitating catastrophic hypertensive encephalopathy, acute aortic dissection, or fatal MI.

---

6. Hypopituitarism & Posterior Pituitary Osmoregulatory Disorders

+---------------------------------------------------------------------------------------------------+
|                         DIABETES INSIPIDUS VS. SIADH COMPARISON MATRIX                            |
|                                                                                                   |
|   FEATURE               DIABETES INSIPIDUS (DI)             SIADH                                 |
|   ---------------------------------------------------------------------------------------------   |
|   Pathophysiology       Deficient ADH Secretion (Central)   Excess Autonomous ADH Secretion       |
|                         or Renal ADH Resistance (Nephrogenic)                                     |
|   Primary Etiologies    • Central: Trauma, Pituitary sx,    • Small cell lung cancer, CNS lesion, |
|                           idiopathic, histiocytosis         • SSRIs, carbamazepine, pneumonia     |
|                         • Nephrogenic: Lithium, hypercalcemia                                     |
|   Urine Output          Massive Polyuria (3 to 20 L/day)    Oliguria / Concentrated Urine         |
|   Serum Sodium          **HYPERNATREMIA** ($>145\text{ mEq/L}$) **HYPONATREMIA** ($<135\text{ mEq/L}$) |
|   Serum Osmolality      **HIGH** ($>295\text{ mOsm/kg}$)    **LOW** ($<275\text{ mOsm/kg}$)       |
|   Urine Osmolality      **INAPPROPRIATELY DILUTE (<300)**   **INAPPROPRIATELY CONCENTRATED (>100)**|
|   Urine Sodium          Low / Variable                      **HIGH** ($>30\text{--}40\text{ mEq/L}$) |
|   Volume Status         Euvolemic to Hypovolemic            **CLINICALLY EUVOLEMIC** (No edema)   |
|   Treatment Strategy    • Central: **Desmopressin (dDAVP)** • **Fluid Restriction (<800-1000 mL)**|
|                         • Nephro: HCTZ, Amiloride, Hydration• Oral Salt tabs + Loop diuretics     |
|                                                             • Hypertonic 3% Saline for severe fx  |
+---------------------------------------------------------------------------------------------------+

A. Diabetes Insipidus Diagnostic Differentiation

• Water Deprivation Test: Withhold fluids while monitoring urine osmolality hourly. Normal individuals concentrate urine ($>600\text{ mOsm/kg}$). Patients with DI continue to pass dilute urine ($<300\text{ mOsm/kg}$) with rising serum sodium and osmolality.
• Desmopressin (dDAVP) Challenge: Administer synthetic dDAVP ($2\text{--}4\text{ mcg SubQ}$ or $10\text{ mcg}$ intranasal):
  • Central DI: Urine osmolality increases by $>50%$ (kidneys respond to exogenous ADH). Treated with oral or intranasal Desmopressin (dDAVP).
  • Nephrogenic DI: Urine osmolality fails to increase or rises $<50%$ (collecting ducts are resistant). Treated with thiazide diuretics (induces mild volume depletion stimulating proximal sodium/water reabsorption), amiloride (for lithium-induced DI), and adequate hydration.

B. Syndrome of Inappropriate Antidiuretic Hormone (SIADH)

• Diagnostic Criteria: Hypotonic euvolemic hyponatremia, elevated urine osmolality ($>100\text{ mOsm/kg}$, usually $>300$), elevated urine sodium concentration ($>30\text{ mEq/L}$), with normal renal, adrenal, and thyroid function, in the absence of diuretic use.
• Emergency Sodium Correction Limit (The Osmotic Demyelination Rule): In acute severe symptomatic hyponatremia (seizures, coma), administer 3% Hypertonic Saline via continuous infusion to raise serum sodium by 4–6 mEq/L rapidly. However, never exceed a correction rate of 8 to 10 mEq/L in any 24-hour period. Overly rapid correction of chronic hyponatremia triggers irreversible Osmotic Demyelination Syndrome (Central Pontine Myelinolysis), leading to spastic quadriparesis, pseudobulbar palsy, "locked-in" syndrome, and death.

---

7. Board-Yield Summary & Clinical Pearls

+---------------------------------------------------------------------------------------------------+
|                                 ANCC AGPCNP CLINICAL EXAM PEARLS                                  |
|                                                                                                   |
|   - Addison's vs. Secondary AI Distinction: Hyperpigmentation + Hyperkalemia = Addison's Disease. |
|     Secondary/Tertiary AI (steroid withdrawal) has Alabaster Pale Skin + Normal Potassium.        |
|                                                                                                   |
|   - Adrenal Crisis Rule: Never wait for lab results to treat suspected adrenal crisis! Give STAT   |
|     IV Normal Saline + Dextrose + IV Hydrocortisone 100 mg. (Use Dexamethasone if testing pending).|
|                                                                                                   |
|   - Cushing's Screening Mandate: Requires AT LEAST 2 abnormal first-line tests: 24-hr Urinary      |
|     Free Cortisol, Late-Night Salivary Cortisol, or 1-mg Overnight Dexamethasone Suppression Test. |
|                                                                                                   |
|   - Pheochromocytoma Blockade Sequence: ALWAYS Alpha-block (Phenoxybenzamine) BEFORE Beta-blocker  |
|     (Propranolol) to prevent fatal unopposed alpha-1 hypertensive crisis.                         |
|                                                                                                   |
|   - Hyponatremia Sodium Correction Speed: Never correct chronic hyponatremia faster than           |
|     8-10 mEq/L per 24 hours to prevent fatal Central Pontine Myelinolysis (Osmotic Demyelination). |
+---------------------------------------------------------------------------------------------------+